134P Impact of pre-operative MammaPrint/BluePrint use for final treatment decisions in patients with stage II/IIIa HR+/HER2- early-stage breast cancer eligible for neoadjuvant chemotherapy: The DETERMIND study
Title:
134P Impact of pre-operative MammaPrint/BluePrint use for final treatment decisions in patients with stage II/IIIa HR+/HER2- early-stage breast cancer eligible for neoadjuvant chemotherapy: The DETERMIND study
Author:
Marin-Liebana, S. Morales, S. Torres, A. Anton Iranzo, V. Zotano, A.L. Guerrero Ponce, J. Adrover, E. Sanchez-Rovira, P. Martorell, A. Perello Merino, L. de la Cruz Borrego, M. Ruiz Toral, J.C. Ayala de la Pena, F. Cussac, A. Llombart